Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nelfinavir desensitization.

P E Abraham1, S J Sorensen, W H Baker

  • 1Department of Pharmacy and Drug Information, Grady Health System, Atlanta, GA 30335-3801, USA. pabraham@gmh.edu

The Annals of Pharmacotherapy
|May 11, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proceedings of the Rochester Hahnemannian Society.

The Homoeopathic physician·2023
Same author

Report of Rochester Hahnemannian Society.

The Homoeopathic physician·2023
Same author

Proceedings of the Rochester Hahnemannian Society.

The Homoeopathic physician·2023
Same author

Rochester Hahnemannian Society.

The Homoeopathic physician·2023
Same author

Proceedings of Rochester Hahnemannian Society.

The Homoeopathic physician·2023
Same author

Proceedings of Rochester Hahnemannian Society.

The Homoeopathic physician·2023
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

This study reports the first successful rapid desensitization to nelfinavir, an important protease inhibitor, for a patient with Human Immunodeficiency Virus (HIV) who experienced severe rashes from other protease inhibitors. This method offers a new treatment option for HIV patients with drug intolerances.

Area of Science:

  • Infectious Diseases
  • Clinical Pharmacology
  • Immunology

Background:

  • Protease inhibitors are crucial for managing Human Immunodeficiency Virus (HIV) infection.
  • Adverse effects, such as skin rashes, can limit the use of protease inhibitors.
  • Limited treatment options exist for HIV patients intolerant to multiple protease inhibitors.

Observation:

  • A 43-year-old male with HIV developed rashes to multiple protease inhibitors.
  • Nelfinavir was tolerated longer than other agents, prompting desensitization.
  • A rapid, six-hour inpatient desensitization protocol was employed.

Findings:

  • The patient successfully tolerated the nelfinavir desensitization procedure without adverse events.
  • HIV disease management was achieved with sustained viral load control.

Related Experiment Videos

  • Rash recurrence was prevented, allowing continued protease inhibitor therapy.

    • Implications:

    • Rapid desensitization is a viable strategy for HIV patients with protease inhibitor-induced rashes.
    • This technique expands therapeutic options for complex HIV treatment scenarios.
    • Successful desensitization can improve long-term management and outcomes for HIV-infected individuals.